Glyciphage-VG1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, mitigating postprandial hyperglycemia. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering improved overall glycemic management. Glyciphage-VG1 Tablet SR is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults when monotherapy or dual therapy has proven insufficient. The sustained-release formulation ensures a gradual and prolonged drug release, minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This medication should be used under medical supervision, with attention to potential hypoglycemia risk due to Glimepiride.